## ICMJE DISCLOSURE FORM

Date:March 3 202	3
Your Name:_Karl-Erik A	ndersson
Title: Cellular regen	erative therapy in stress urinary incontinence: New frontiers?
Manuscript number (if k	(nown): TAU-22-682

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	X_None		
	speakers bureaus,			
	manuscript writing or			
	educational events	V. Nana		
6	Payment for expert testimony	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
	, 			
8	Patents planned, issued or	None	CXCL12 for Sphincter Dysfunction	
	pending			
9	Participation on a Data	X None		
9	Safety Monitoring Board or	_XNone		
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	X None		
11	Stock of Stock options	x_none		
12	Receipt of equipment,	_XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	_XNone		
	financial interests			
	Please summarize the above conflict of interest in the following box:  We have applied for a patent that covers CXCL12 for sphincter dysfunction (urinary, anal).			
V	re nave applied for a paterit tild	at covers cycriz for shillinger	aystuticuoti (attitaty, attatj.	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:	March 2, 2023	
Your Name:	James Koudy Williams	
Manuscript '	Title: Cellular regenerativ	ve therapy in stress urinary incontinence: New frontiers?
Manuscript	 number (if known) TAU-22-68	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X _ None	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	NIH _None	RO1 from NIDDK
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

_	Decimand and a control of	V No.	
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	•		
7	Support for attending	X None	
,	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	None	CXCL12 for Sphincter Dysfunction
	pending		Sixella is a sprimate of parameters
	perioring		
0	Double in chien and Dobe	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12		^_NOTE	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

## Please summarize the above conflict of interest in the following box:

om NIDDK.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.